Local immune reaction in nasopharyngeal carcinoma, with special reference to its prognostic evaluation

Pathobiology of selected tumors of the base of the skull

Skull base surgery is a new subspeciality, and, up to this point, most articles on this subject have focused on innovative operative-reconstructive approaches to tumors in this region. It is now important that we embark on a new era, the era of tumor biology, and concentrate on new ways of evaluating these neoplasms from a pathologic viewpoint. The hematoxylin-cosin section is no longer an end point, but just a beginning. This is the age of molecular biology. It is important that these tumors be evaluated, either prospectively or retrospectively, employing immunohistochemical staining, flow cytometry, oncogene expression, cytogenetics, or other techniques in order to identify important prognostic features. Data from these additional studies may then be used to develop new treatment strategies. Skull base societies should develop protocols for one or more of these tumors to ensure that they are indeed evaluated uniformly. In this article I emphasize the importance of accurate histologic classification or subclassification of these neoplasms and focus on contemporary parameters that may or may not impact on prognosis.

New viewpoint to histological classification of malignant epithelial tumors of nasopharynx

Malignant tumors of nasopharyngeal epithelium differ clinically depending on the course of disease and applied therapy. They are presented in regard to the sex, age, smoking habits, alcohol usage and nutrition factors. Various studies already showed various etiological-causal links with Epstein- Barr virus (EBV). This leads to diversity of various morphological and histological types of diseases belonging to various classifications. In this work we presented 60 diagnosed and treated cases with malignant tumor of nasopharyngeal epithelium in the Institute for Otorynolaringology and maxillofacial surgery of Clinical Center of Serbia. All of them were pato-histologicaly examined and 24 of them received serological examination in regard to the concept of association between malignant epithelial tumor and EBV. An important correlation between histopathology and serology was found. Finally, the terminology used by WHO classification is not optimal for further histological determination of nasopharyngeal malignancy; therefore we recommend the French classification of C. Micheaua.

Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma

BACKGROUND

In nasopharyngeal carcinoma (NPC), Fas-ligand (Fas-L)-mediated apoptosis might contribute to the immune privilege of tumors. In some cancers, dysregulation of Fas-L protein in tumors might lead to disease progression. The purpose of this study was to evaluate the correlations between Fas-L expression and the clinical outcomes in patients with NPC.

METHODS

We recruited 78 patients with primary NPC, classified clinical stages according to the 1997 American Joint Committee on Cancer staging system, and assessed Fas-L with immunohistochemical methods.

RESULTS

Forty-one (53%) of 78 patients were Fas-L-positive. The prevalence was 0%, 57%, 58%, and 82% from stages I to IV, respectively (p <.001). Fas-L expression was associated with the N classification (p=.05) but not the T classification. Patients with positive Fas-L expression had a lower rate of disease-free survival and overall survival (p=.01 for all log-rank tests).

CONCLUSION

Patients with NPC with Fas-L-positive tumors had higher clinical stages and lymph node metastasis at diagnosis and poorer disease-free survival and overall survival; therefore, Fas-L expression may be a potential biomarker of prognosis.

Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues

Nasopharyngeal carcinoma (NPC) is an epithelial cancer with a high incidence in Southeast Asia. How it escapes attack from the host immune system is not fully understood. Recently, pieces of evidence show that Fas-ligand (Fas-L)-mediated apoptosis may be involved in immune privilege of tumours. To determine whether a similar mechanism may exist in NPC, the expression of Fas-L was analysed. Biopsy specimens of the nasopharynx were taken from 27 NPC patients. Histologically, they were either non-keratinizing or undifferentiated carcinomas. Nasopharyngeal biopsies of 11 other patients that proved to have no tumour served as control. The transcripts of Fas-L were detected by reverse transcription-polymerase chain reaction. Localization of Fas-L protein was performed with immunohistostaining using an antibody recognizing human Fas-L. All nasopharyngeal tissues have a similar amount of transcripts of Fas-L. However, the Fas-L protein was detected exclusively on the cell surface of malignant epithelial cells of NPC. The present findings suggest that Fas-L protein may be involved in evading immune attack of NPC.

The biology and pathology of selected skull base tumors

This paper describes the pathobiology of some of the more common skull base tumors. In addition to clinicopathologic features, emphasis is placed upon methods of diagnosis utilizing immunoperoxidase stains and molecular markers that may or may not impact upon prognosis.

Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma

The authors performed a retrospective analysis of serum soluble interleukin-2 receptor (sIL-2R) levels in 72 patients with nasopharyngeal carcinoma (NPC) using an enzyme immunoassay. Their objectives were to determine the value of serum sIL-2R in estimating the tumor burden, and its predictive value in response to therapy and prognosis. The data showed that serum sIL-2R levels in patients were significantly higher than that of healthy controls. The serum levels correlated with clinical staging and hence the tumor burden of NPC. Serial measurement of serum sIL-2R provided an accurate prognostic index of the clinical response to radiotherapy in at least 89% of patients with raised serum sIL-2R at initial diagnosis (defined as mean + 2 SD of healthy controls) and a reliable predictive index in all patients who subsequently developed distant metastasis despite initial radiotherapy. Simultaneous measurement of Epstein-Barr virus-related serology (IgA-VCA and IgG-EA) failed to demonstrate predictive value comparable with that of serum sIL-2R. The authors conclude that monitoring serum sIL-2R levels has clinical and prognostic significance in patients with NPC and that prospective studies are indicated.